From botanical waste to a biocatalyst: Kigelia pinnata flower-derived CQDs for triazolidine-3-thione synthesis and their in silico evaluation
Abstract
Biowaste-derived carbon quantum dots (CQDs) have emerged as sustainable, low-cost nanomaterials that align with the principles of green chemistry and promote waste-to-wealth conversion. In this work, CQDs were synthesized using drop-down flowers of Kigelia pinnata as a novel biowaste carbon source via a green hydrothermal method. The resulting CQDs were comprehensively characterized by HRTEM, FT-IR, UV-visible, fluorescence spectroscopy, EDS, and XRD, revealing well-dispersed spherical particles with an average diameter of 3.78 nm. They showed excellent catalytic activity as an efficient nanocatalyst for the green synthesis of 1,2,4-triazolidine-3-thione derivatives using ethanol : water (1 : 4) mixture at RT, affording excellent yields (82–97%) in short reaction times (5–20 min). Three of the nine synthesized compounds are new, and the catalyst was reusable for up to six runs without significant loss of activity. The protocol offers key advantages, viz., broad substrate scope, mild conditions, gram-scale feasibility, and favorable green chemistry metrics. Furthermore, all the synthesized compounds were screened for biological activity using PASS prediction, followed by molecular docking with 17β-dehydrogenase (4DBW) and pterin deaminase (3H23). The docking studies showed stable interactions and favorable binding energies, suggesting good affinity for both enzymes. The compounds also exhibited promising drug-like behavior based on ADMET analysis.
How strong is the evidence?
Evidence Hub reads this as a experimental / empirical study, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.